GlobalMinds: a global genetic and health-record database to improve personalized care for people with serious mental illness and dementia
Official title: Developing an Internationally-diverse, Linked Genomic and Longitudinal Phenotypic Research Dataset to Accelerate Precision Psychiatry for Patients With Serious Mental Illness
Run by Akrivia Health · NCT06641726 · Data updated 2026-11-12
This project will collect whole-genome data and linked health records from 50,000 adults with major mental illnesses or dementia to see if combining genetic and clinical information can help personalize diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 110 Years |
| Sex | All |
| Enrollment | 50000 (estimated) |
| Sponsor | Akrivia Health Industry-sponsored |
| Locations | 1 site (Oxford, Oxford) |
| Status | Recruiting |
| Started | May 16, 2025 |
| Main results expected | January 1, 2035 |
| Study ends | July 1, 2035 |
| Registry record updated | October 3, 2025 |
| Trial ID | NCT06641726 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with an accessible electronic health record who have been diagnosed with or referred/treated for major depressive disorder, bipolar disorder, schizophrenia, or dementia, who can consent, communicate in English, and (for dementia participants) complete a validated cognitive assessment.
✕Probably not a fit
People without capacity to give consent, those lacking an accessible electronic health record, non-English speakers who cannot complete study procedures, and individuals under 18 are not eligible and therefore will not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
GlobalMinds will enroll 50,000 adults with bipolar disorder, schizophrenia, major depressive disorder, or dementia and collect biological samples alongside their electronic health records. The program will perform whole genome sequencing and additional biomarker analyses, then link those data to longitudinal clinical information available through the Akrivia Health platform. Investigators will apply advanced analytic approaches to explore new ways of grouping symptoms, predicting outcomes, and identifying biologically informed subtypes. The resource will be made available to qualified researchers to accelerate development of targeted diagnostics and treatments.
Why it matters
Potential benefit: If successful, this resource could lead to more accurate diagnoses, better prediction of illness course, and more personalized treatment options for people with serious mental illness and dementia.
How similar studies have gone: Large genomic and EHR-linked efforts (for example UK Biobank and work from the Psychiatric Genomics Consortium) have identified genetic associations and shown promise, but translation into routine personalized psychiatric care remains limited, so this program builds on promising but still-emerging evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- All participants must have an electronic health record in a primary or secondary care service. Mental Health cohort(s) • Have received a diagnosis and/or treatment/referral for mental illness for MDD, BD, Schizophrenia. • Having an available electronic health record • Current age 18+ (no upper age limit) • Can speak English Dementia cohort • Participants aged 18+ (no upper age limit) • Currently alive and are, or have been, old age psychiatry patients • Received relevant diagnosis or referral: EITHER • Clinical diagnosis of dementia, mild cognitive impairment (MCI) or subjective cognitive impairment (SCI) OR • Memory clinic referral • Must be willing and able to complete a validated cognitive assessment (MoCA or SLUMS). All dementia patients will undergo the extended biomarker analysis. Exclusion Criteria: \- Mental Health cohort(s) • Patients without capacity to provide consent. Dementia cohort • Inability to understand spoken and/or written spoken English • Individuals with intellectual disability. • Patients with dementia in Creutzfeldt-Jakob disease (CJD), Huntington's, HIV dementia, alcohol-related dementia, intellectual disability, traumatic brain injury at any time. • Patients diagnosed with depression (only an exclusion criterion for MCI/SCI patients), psychosis, bipolar disorder prior in the pre-index period - to be checked at screening.
Where it's running
-
GlobalMinds central study team
Oxford, Oxford, United Kingdom Recruiting
Study contacts
- Principal investigator: Prof. James Walters — Cardiff University
- Study coordinator: Samantha Yuille, PhD
- Email: samantha.yuille@akriviahealth.com
- Phone: (44) 7827018555
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using an epigenetic drug to boost virtual reality cognitive training for middle-aged and older adults with depression or bipolar disorder
This trial will test whether daily sodium butyrate combined with three weeks of virtual reality cognitive training improves thinking skills in symptomatically stable adults aged 40–75 with depression or bipolar disorder.
-
Precision treatment strategies for common mental disorders
This study is testing a personalized approach to treating common mental health conditions like depression and schizophrenia by using genetic information to help choose the right medications for people.
-
Diabetes, Dementia, and Oxidative Stress: A look at Nox2-related markers
This study tests whether oxidative stress linked to Nox2 is related to dementia risk in adults with type 2 diabetes.
-
Affective Cognitive Training for mood disorders and their close relatives
A six-week program combining virtual reality and computer exercises tests whether affective cognitive training helps people with mood disorders and their unaffected first-degree relatives.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Doll Therapy for Apathy and Daily Living in Older Adults with Dementia
This study tests whether doll therapy helps reduce apathy and improves starting daily activities in older adults with dementia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.